Overview
Pro Medicus sells software that helps healthcare providers manage radiology workflows and view medical images. Its international reach and supplied revenue growth of 18.20% support the business case, while a A$16.3 billion market capitalisation and a price-to-earnings ratio of 61.81 put expectations and valuation firmly in focus. The shares recently traded at A$156.38, below both supplied moving averages and well within a broad 52-week range.
Pro Medicus is an Australian healthcare informatics company whose software supports medical imaging workflows for hospitals, imaging centres and healthcare groups in Australia, Europe and North America. Its products include radiology information systems and the Visage 7 Enterprise Imaging Platform, which enables clinicians to access and view medical images. The business also provides implementation, training and support services. The supplied figures show trailing revenue of A$261.7 million and revenue growth of 18.20%, with a market capitalisation of A$16.3 billion.
Key facts
- Ticker
- PME
- Exchange
- AU
- ISIN
- AU000000PME8
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- Australia
- Currency
- AUD
- Price
- A$156.38
- Previous close
- A$161.09
- Day change
- -A$4.71 (-2.92%)
- Market cap
- 16.3B
- 52W low
- A$107.22
- 52W high
- A$314.72
Price and trend
Last price: A$156.38
- Price
- A$156.38
- 52W range
- A$107.22 – A$314.72
- 50-day SMA
- A$173.16
- 200-day SMA
- A$161.17
- Price vs 50D SMA
- -9.69%
- Price vs 200D SMA
- -2.97%
Valuation
- P/E
- 61.81
- PEG
- 2.67
- EPS
- 2.53
- Dividend yield
- 0.43%
- Beta
- 0.58
Pro Medicus is priced at a premium on the supplied measures, with a price-to-earnings ratio of 61.81 and a PEG ratio of 2.67. Revenue growth of 18.20% offers a business-performance counterpoint, but the valuation makes the shares sensitive to any disappointment in growth expectations. The 0.43% dividend yield contributes little current income relative to the valuation story.
Profitability and growth
- Revenue growth
- 18.20%
- Revenue TTM
- 261.7M
- Profit margin
- 101.40%
Analyst view
Comparison uses the last price shown; targets are analyst estimates.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
- Price
- A$156.38
- Target price
- A$202.47
- Target vs last price
- 29.47% from last price
The central question for investors is whether Pro Medicus can sustain growth in a specialist healthcare software market while supporting a premium valuation. The business has an international customer base and the supplied revenue growth is 18.20%, but the share price’s position below its 50-day and 200-day moving averages points to softer recent price momentum. That technical context is secondary to the company’s ability to convert demand into durable operating performance.
Risks
Pro Medicus’s valuation leaves the shares exposed if growth or market expectations soften: the supplied price-to-earnings ratio is 61.81 and PEG ratio is 2.67. The dividend yield of 0.43% is modest, and the share price has recently traded below both supplied moving averages. Its reported profit margin of 101.40% is unusually high; investors may wish to understand the basis of that figure before relying on it as a guide to ongoing profitability. The shares have also ranged widely over the past year, from A$107.22 to A$314.72.
FAQ
What does Pro Medicus do?
Pro Medicus supplies medical imaging and information software to hospitals, imaging centres and healthcare groups. Its offerings include radiology information systems and the Visage 7 Enterprise Imaging Platform, which helps clinicians view and work with medical images.
How has Pro Medicus been growing?
The supplied figures show revenue growth of 18.20% and trailing revenue of A$261.7 million. These figures provide context for a business whose software and services are used across Australia, Europe and North America.
What is Pro Medicus’s dividend profile?
The indicated dividend yield is 0.43%, so the shares have a relatively low yield profile based on the supplied figure. The investment case is therefore more closely tied to the company’s operating performance and valuation than to current income.
How does PME’s share price compare with its recent trading range?
At A$156.38, the share price is between the supplied 52-week low of A$107.22 and high of A$314.72. It is below both the 50-day moving average of A$173.16 and the 200-day moving average of A$161.17, indicating weaker recent price performance against those measures.
*This content is aimed to provide general information only, and does not take your personal objectives, financial situation or needs into account.
Pro Medicus Limited (ASX: PME) Fundamentals
Pro Medicus Limited (ASX: PME) Competitors
